Alexander A. Peterson

Alexander A. Peterson

Auto-generated profile, based on publicly available information

Alexander A. Peterson

Department of Chemistry, The Scripps Research Institute, La Jolla, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
APAlexander A. Peterson
Alexander A. Peterson
DLDavid R. Liu
David R. Liu

26 September 2022 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
APAlexander A. Peterson
Alexander A. Peterson
ARAziz M. Rangwala
Aziz M. Rangwala
MTManish K. Thakur
Manish K. Thakur
PWPatrick S. Ward
Patrick S. Ward
CHChristie Hung
Christie Hung
DLDavid R. Liu
David R. Liu
Although cyclophilins are attractive targets for probing biology and therapeutic intervention, no subtype-selective cyclophilin inhibitors have been described. We discovered novel cyclophilin inhibitors from the in vitro selection of a DNA-templated library of 256,000 drug-like macrocycles for cyclophilin D (CypD) affinity. Iterated macrocycle engineering guided by ten X-ray co-crystal structures yielded potent and selective inhibitors (half maximal inhibitory concentration (IC50) = 10 nM) that bind the active site of CypD and also make novel interactions with non-conserved residues in the S2 pocket, an adjacent exo-site. The resulting macrocycles inhibit CypD activity with 21- to >10,000-fold selectivity over other cyclophilins and inhibit mitochondrial permeability transition pore opening in isolated mitochondria. We further exploited S2 pocket interactions to develop the first cyclophilin E (CypE)-selective inhibitor, which forms a reversible covalent bond with a CypE S2 pocket lysine, and exhibits 30- to >4,000-fold selectivity over other cyclophilins. These findings reveal a strategy to generate isoform-selective small-molecule cyclophilin modulators, advancing their suitability as targets for biological investigation and therapeutic development.

11 September 2024 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ACAlan Costello
Alan Costello
APAlexander A. Peterson
Alexander A. Peterson
DLDavid L. Lanster
David L. Lanster
ZLZhiyi Li
Zhiyi Li
GCGavriela D. Carver
Gavriela D. Carver
ABAhmed Badran
Ahmed Badran

7 October 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
ACAlan Costello
Alan Costello
APAlexander A. Peterson
Alexander A. Peterson
DLDavid L. Lanster
David L. Lanster
ZLZhiyi Li
Zhiyi Li
GCGavriela D. Carver
Gavriela D. Carver
ABAhmed Badran
Ahmed Badran